Form 4: Bio-Techne Director Sells Shares in Routine Transaction
Insider Transaction Report
Amy E. Herr, a Director at Bio-Techne Corp, reported the sale of 1,976 shares of common stock for approximately $59.11 per share.
Summary
- Amy E. Herr, a Director of Bio-Techne Corp (TECH), sold 1,976 shares of common stock on February 17, 2026.
- The shares were sold at a weighted average price of $59.105, with individual transactions ranging from $59.091 to $59.1390.
- Following the transaction, Ms. Herr directly beneficially owns 2,680 shares of common stock.
- An additional 200 shares are indirectly beneficially owned by a significant other.
- Ms. Herr also holds various derivative securities, including stock options and restricted stock units, both directly and indirectly through a significant other, with various exercise prices and vesting schedules extending to 2035.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. While an insider sale can sometimes be perceived negatively, this transaction appears to be a routine personal financial management activity by a director, not signaling a significant change in company prospects.
Positives
- The sale could indicate a diversification strategy or liquidity needs for the reporting person.
- The reporting person retains a significant number of direct and indirect shares, as well as substantial derivative holdings, indicating continued alignment with shareholder interests.
Negatives
- An insider sale by a director could be interpreted by some investors as a lack of confidence in the company's near-term stock performance, although the amount sold is relatively small compared to total holdings.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that insider sales, while sometimes interpreted negatively, are common for directors managing personal portfolios, especially given the long vesting schedules of their equity awards. The biotech industry often sees executives holding significant equity, and periodic sales for diversification or liquidity are not unusual.
Comparison to Industry Standards
- StockSavvy.ai observes that the sale of 1,976 shares by a director is a relatively minor transaction compared to the total outstanding shares of Bio-Techne Corp and the director's remaining holdings, including substantial derivative securities.
- For instance, similar insider sales by directors at comparable biotech firms like Thermo Fisher Scientific (TMO) or Danaher Corporation (DHR) often occur for personal financial planning and are typically not indicative of a fundamental shift in company outlook unless they represent a significant portion of the insider's total holdings or are part of a broader pattern of sales across multiple insiders.
Related Party Transactions
- The transaction involves a director of Bio-Techne Corp selling company stock, which is inherently a related party transaction as defined by SEC regulations for insider reporting.
Stakeholder Impact
- Shareholders: May interpret the sale as a minor negative signal, but the limited size and continued significant holdings suggest minimal impact on overall confidence.
- Employees: No direct impact.
- Customers: No direct impact.
- Suppliers: No direct impact.
- Creditors: No direct impact.
Key Dates
| Date | Description |
|---|---|
| 2023-08-15 | Vesting date for 528 shares of stock options (part of 2,104 total options granted 08/15/2029). |
| 2024-08-15 | Vesting date for 524 shares of stock options (part of 2,104 total options granted 08/15/2029) and 271 shares of stock options (part of 1,084 total options granted 08/15/2030). |
| 2025-08-15 | Vesting date for 528 shares of stock options (part of 2,104 total options granted 08/15/2029) and 271 shares of stock options (part of 1,084 total options granted 08/15/2030) and 367 shares of stock options (part of 1,468 total options granted 08/15/2034). |
| 2025-10-24 | Date exercisable for 2,415 stock options with an exercise price of $72.05. |
| 2025-10-30 | One-year anniversary of grant date for 3,777 stock options, or the date of Bio-Techne's 2026 annual meeting of shareholders, whichever is earlier, for vesting. |
| 2026-02-03 | Vesting date for 86 shares of stock options (part of 344 total options granted 02/03/2035). |
| 2026-02-17 | Date of common stock sale transaction by Amy E. Herr. |
| 2026-02-19 | Signature date of the Form 4 filing. |
| 2026-08-07 | Expiration date for 6,636 fully vested stock options with an exercise price of $47.60. |
| 2026-08-15 | Vesting date for 524 shares of stock options (part of 2,104 total options granted 08/15/2029), 271 shares of stock options (part of 1,084 total options granted 08/15/2030), 367 shares of stock options (part of 1,468 total options granted 08/15/2034), 118 restricted stock units, 160 restricted stock units (part of 320 total), 311 restricted stock units (part of 932 total), and 912 shares of stock options (part of 2,735 total options granted 08/15/2035). |
| 2027-02-03 | Vesting date for 86 shares of stock options (part of 344 total options granted 02/03/2035) and 38 restricted stock units (part of 77 total). |
| 2027-08-05 | Expiration date for 4,472 fully vested stock options with an exercise price of $66.97. |
| 2027-08-15 | Vesting date for 271 shares of stock options (part of 1,084 total options granted 08/15/2030), 367 shares of stock options (part of 1,468 total options granted 08/15/2034), 160 restricted stock units (part of 320 total), 311 restricted stock units (part of 932 total), and 912 shares of stock options (part of 2,735 total options granted 08/15/2035). |
| 2028-02-03 | Vesting date for 86 shares of stock options (part of 344 total options granted 02/03/2035) and 39 restricted stock units (part of 77 total). |
| 2028-08-06 | Expiration date for 2,076 fully vested stock options with an exercise price of $120.46. |
| 2028-08-15 | Vesting date for 367 shares of stock options (part of 1,468 total options granted 08/15/2034), 310 restricted stock units (part of 932 total), and 911 shares of stock options (part of 2,735 total options granted 08/15/2035). |
| 2029-02-03 | Vesting date for 86 shares of stock options (part of 344 total options granted 02/03/2035). |
| 2029-08-15 | Expiration date for 2,104 stock options with an exercise price of $94.52. |
| 2030-08-15 | Expiration date for 1,084 stock options with an exercise price of $84.61. |
| 2034-08-15 | Expiration date for 1,468 stock options with an exercise price of $74.91. |
| 2035-02-03 | Expiration date for 2,415 stock options with an exercise price of $72.05 and 344 stock options with an exercise price of $72.05. |
| 2035-08-15 | Expiration date for 2,735 stock options with an exercise price of $53.60. |
| 2035-10-30 | Expiration date for 3,777 stock options with an exercise price of $60.96. |
Recommendation
holdThe reported insider sale by a director is a routine personal financial transaction and does not provide sufficient new information to alter an investment thesis for Bio-Techne Corp. The director retains substantial equity holdings, suggesting continued alignment. Investors should hold their positions and focus on broader company fundamentals and industry trends rather than this isolated transaction.
Keywords
Bio-Techne, TECH, Insider Trading, Form 4, Stock Sale, Director, Amy E. Herr, Equity Transaction, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.